| | July 20198IN MY OPINIONA rtificial Intelligence (AI) is the ability of a computer or machine to simulate human intelligence and is dependent on three elements: massive amounts of data, sophisticat-ed algorithms, and high-performance parallel processors. It is a broad term encompassing various ways in which computers process and find patterns within complex information and gen-erate inferences or predictions from that data.The idea of using artificial intelli-gence (AI) to accelerate drug discov-ery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. It can be applied to various types of healthcare data (structured and un-structured). The increasing availability of healthcare data and rapid development of big data ana-lytic methods have made possible the recent successful applications of AI in healthcare. With the ability to find hidden and unintuitive patterns in vast amounts of data in ways that no human can do, AI represents a considerable promise to transform many industries, including phar-ma and biotech.AI in Various Phases of R&DWith more comprehen-sive understanding of the biologi-cal basis of disease through AI, the R&D process will be more stream-lined to develop therapies from the offset, with optimal trial and er-rors. Reducing the failure rate will in turn save the industry billions of dollars. By Ravi Sekhar Kasibhatta, Senior Vice President, Lupin Bioresearch CenterIn his carrier spanning over three decades, Ravi has played instrumental roles in several pharmaceutical companies and is currently responsible for running Lupin Bioresearch Center to conduct BA/BE studies for several regulated markets in support of generic product development. SCIENTIFIC & TECHNOLOGICAL (AI BASED) ADVANCEMENT IN PHARMACEUTICAL R&D & CLINICAL TRIALSRavi Sekhar Kasibhatta
< Page 7 | Page 9 >